Phase 3 Randomized Open-Label Study of Nivolumab and Ipilimumab Versus Sunitinib in Treatment-Naïve Advanced or Metastatic Renal Cell Carcinoma

The primary objective of this study is to compare the **progression-free survival** and **overall survival** of patients with previously untreated advanced or metastatic renal cell carcinoma when treated with a combination of nivolumab and ipilimumab versus sunitinib monotherapy. This comparison is clinically relevant as it aims to determine the efficacy of the combination therapy in extending the time patients live without disease progression and overall survival, which are critical endpoints in the management of renal cell carcinoma.

Secondary objectives include evaluating:

• **Progression-free survival**
• **Overall survival**
• **Objective response rate**
• **Duration of objective response**
• **Overall safety and tolerability**
• **Disease-related symptom progression**
• **Health-related quality of life**
• **Healthcare resource utilization**

The clinical trial involves a total of **777 participants** diagnosed with **advanced or metastatic renal cell carcinoma**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected based on specific criteria, including a histological confirmation of renal cell carcinoma with a clear-cell component and a Karnofsky Performance Status of at least 70%. The trial includes individuals who have not received prior systemic therapy for renal cell carcinoma, except for certain adjuvant or neoadjuvant therapies. The health status of participants is characterized by measurable disease as per RECIST 1.1 guidelines. The trial population also includes vulnerable groups, ensuring a comprehensive evaluation of the treatment's efficacy across diverse demographics. Lifestyle factors such as diet and physical activity are not specified in the available data. The sponsor has not provided additional information regarding specific lifestyle considerations or other demographic details.

The clinical trial is a **Phase 3**, randomized, open-label study designed to evaluate the efficacy of **nivolumab** combined with **ipilimumab** versus **sunitinib** monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma. The primary endpoints of the study are overall survival and progression-free survival, with secondary endpoints including objective response rate, duration of objective response, overall safety and tolerability, disease-related symptom progression, health-related quality of life, healthcare resource utilization, and adverse event incidence rate. The trial is expected to conclude by August 2028, with recruitment having commenced in December 2014.

Participants will be randomly assigned to receive either the combination therapy of nivolumab and ipilimumab or sunitinib monotherapy. The study involves multiple visits, starting with an inclusion (screening) visit to confirm eligibility based on criteria such as histological confirmation of renal cell carcinoma with a clear-cell component, advanced or metastatic disease status, and a Karnofsky Performance Status of at least 70%. Participants must also have measurable disease as per RECIST 1.1 and provide tumor tissue for randomization.

Following the screening visit, participants will undergo regular follow-up visits to monitor treatment response and safety. These visits will include assessments of disease progression, adverse events, and quality of life measures. The end-of-study visit will occur upon completion of the treatment period or earlier if the participant experiences disease progression or unacceptable toxicity. The expected length of participant involvement varies, with a maximum treatment period of 24 months for nivolumab and ipilimumab, and up to 48 months for sunitinib. Conditions that may lead to early termination from the study include significant adverse events, withdrawal of consent, or investigator decision based on clinical judgment.

The clinical trial involves the administration of **Nivolumab**, marketed as OPDIVO, which is provided as a 10 mg/mL **concentrate for solution for infusion**. This pharmaceutical form is intended for **intravenous** administration. The dosing regimen specifies a maximum daily dose of 3 mg/kg, with a total maximum dose of 147 mg/kg over a treatment period of up to 24 months. The active substance, **nivolumab**, is a protein-based therapeutic agent developed by Bristol-Myers Squibb Pharma EEIG. Participant compliance with the dosing schedule will be monitored throughout the study.

Another experimental treatment in the trial is **Ipilimumab**, also provided as a **concentrate for solution for infusion**. This medication is administered **intravenously**. The dosing parameters allow for a maximum daily and total dose of 9999 mg/kg, with no specified maximum treatment period, indicating flexibility in dosing based on clinical judgment. **Ipilimumab** is a protein-based agent developed by Bristol-Myers Squibb International Corporation, and its administration will be closely monitored to ensure adherence to the protocol.

The comparator treatment in this study is **Sunitinib**, marketed as Sutent, available in 12.5 mg **hard capsules**. This medication is administered **orally**. The dosing schedule permits a maximum daily dose of 50 mg, with a total maximum dose of 11200 mg over a treatment period of up to 48 weeks. **Sunitinib** is a chemical-based therapeutic agent developed by Pfizer Europe MA EEIG. Participant adherence to the oral dosing regimen will be monitored to ensure compliance with the study protocol.

The efficacy of the clinical trial will be assessed using primary endpoints of overall survival and progression-free survival in patients with advanced or metastatic **Renal Cell Carcinoma**. Secondary endpoints include objective response rate, duration of objective response, overall safety and tolerability, disease-related symptom progression, health-related quality of life, healthcare resource utilization, and adverse event incidence rate. These endpoints will be measured and analyzed to determine the comparative effectiveness of nivolumab combined with ipilimumab versus sunitinib monotherapy.